Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
J Clin Exp Hepatol
; 9(1): 29-33, 2019.
Article
em En
| MEDLINE
| ID: mdl-30765936
ALT, Alanine Aminotransferase; ECM, Extracellular Matrix; ELISA, Enzyme-Linked Immunosorbent Assay; HRP, Horseradish Peroxidase; HSCs, Hepatic Stellate Cells; MMPs, Matrix Metalloproteinases; NAFLD, Non-Alcoholic Fatty Liver Disease; NIA, Necro-Inflammatory Activity; OD, Optical Densities; PAIs, Plasminogen Activator Inhibitors; TGF-beta, Transforming Growth Factor-beta; TIMPs, Tissue Inhibitors of Metalloproteinases; hepatitis B; hepatitis C; non-alcoholic fatty liver disease; tPA, tissue-type Plasminogen Activator; uPA, urokinase-type Plasminogen Activator; uPAR, urokinase Plasminogen Activator Receptor; urokinease-type plasminogen activator receptor
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article